Board of Directors
Pacira BioSciences, Inc.
Dave Stack is currently the Chief Executive Officer and Chairman of Pacira BioSciences, Inc. He was a Managing Director at MPM Capital from 2005 until 2017.
From September 2001 until August 2004, Mr. Stack
Dave Stack is currently the Chief Executive Officer and Chairman of Pacira BioSciences, Inc. He was a Managing Director at MPM Capital from 2005 until 2017.
From September 2001 until August 2004, Mr. Stack was President and CEO of The Medicines Company (NASDAQ: MDCO). Prior to The Medicines Company, he was the CEO of Stack Pharmaceuticals, Inc., where The Medicines Company was one of its primary customers. From May 1995 to December 1999, he served as the President and General Manager of Innovex, Inc., responsible for the Americas. Innovex, Inc. was a commercial solutions company offering a full range of marketing, sales and clinical development capabilities to pharmaceutical and biotechnology customers, and was sold to Quintiles in November 1997 for $897 million. From April 1993 to May 1995, he was the Vice President of Business Development and Marketing for Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company focusing on monoclonal antibodies in infectious disease and oncology.
Prior to that, he was with Roche Laboratories in positions of increasing responsibility from 1981 until 1993, including Therapeutic World Leader in Infectious Disease and Director, Business Development and Planning, Infectious Disease, Oncology, and Virology. Mr. Stack was a retail and hospital pharmacist for three years after graduating from Albany College of Pharmacy. He also holds a Bachelor of Science in Biology from Siena College, where he and his wife Christine founded The Stack Center for Innovation and Entrepreneurship, where he is currently a Trustee.
Mr. Stack was recognized as the Ernst and Young Entrepreneur of the Year in 2003 (New Jersey Healthcare). He currently serves as a member of the board of directors of Amarin Corporation plc and Prognos AI. Mr. Stack was a member of the boards of directors of Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) from 2006 to 2010 and BioClinica, Inc. (NASDAQ: BIOC) from 1999 to 2010.
Paul J Hastings
CEO of Nkarta Therapeutics, Inc.
Paul Hastings has served as a director since June 2011 and as our Lead Director since June 2013. Mr. Hastings is President and Chief Executive Officer of Nkarta Therapeutics, Inc. and formerly served as President,
Paul Hastings has served as a director since June 2011 and as our Lead Director since June 2013. Mr. Hastings is President and Chief Executive Officer of Nkarta Therapeutics, Inc. and formerly served as President, Chief Executive Officer, a member of the Board of Directors, and Chairman of the Board of OncoMed Pharmaceuticals (NASDAQ: OMED) (“OncoMed”) from 2006 through January 2018.
Mr. Hastings was previously President and Chief Executive Officer of QLT, Inc. Before this role, he served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. Prior to Axys, he was President of Chiron Biopharmaceuticals, and also held a variety of management positions of increasing responsibility at Genzyme Corporation, including President of Genzyme Therapeutics Europe and President of Worldwide Therapeutics. Mr. Hastings was Chairman of the board of directors of Proteolix (sold to Onyx) and was a member of the board of directors of each of ViaCell Inc. (sold to Perkin Elmer) and Relypsa (sold to Galencia).
Mr. Hastings currently serves as Chairman of the board of directors at Proteon Therapeutics, Inc. (NASDAQ: PRTO). He also serves on the board of the California Life Sciences Association and also on the board of directors and executive committee of the Biotechnology Industry Organization.
He received a Bachelor of Science degree in pharmacy from the University of Rhode Island.
Former CEO of Nodality, Inc.
Laura Brege has served as a director since June 2011. Since April 2018, Ms. Brege has served as Senior Advisor to BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic
Laura Brege has served as a director since June 2011. Since April 2018, Ms. Brege has served as Senior Advisor to BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases. From September 2015 to June 2018, she served as Managing Director of Cervantes Life Sciences Partners, LLC., a health care advisory and consulting company. From 2012 to 2015, she served as the President and Chief Executive Officer of Nodality, Inc. Prior to this position, she served as Chief Operating Officer, Executive Vice President, Chief Business Officer, and Head of Corporate Affairs, for Onyx Pharmaceuticals. In this role, Ms. Brege was responsible for the oversight of all external relationships, including medical and scientific affairs, government affairs and public affairs. In these roles, she oversaw the expansion of key corporate capabilities and strengthened the company’s financial position by significantly adding to its cash reserves. Prior to joining Onyx in 2006, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm, and Senior Vice President and Chief Financial Officer at COR Therapeutics.
As of March 15, 2019 Ms Brege left her position as the Audit Chair of Aratana Therapeutics. Ms. Brege currently serves as a director of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD), HLS Therapeutics, a company on the Toronto exchange (TSX: HLS) that markets branded drugs in Canada, and Portola Pharmaceuticals, Inc. (NASDAQ: PTLA). She previously served as a member of the board of directors of Aratana Therapeutics, Inc. (NASDAQ: PETX) from February 2014 until March 2019 and Dynavax Technologies Corporation (NASDAQ: DVAX) from 2015 until 2020.
Ms. Brege earned her undergraduate degree from Ohio University and has an MBA from the University of Chicago.
Governor Chris Christie has served as a director since September 2019. Chris Christie was inaugurated as the 55th Governor of the State of New Jersey on January 19, 2010. He was re-elected in November of 2013 and
Governor Chris Christie has served as a director since September 2019. Chris Christie was inaugurated as the 55th Governor of the State of New Jersey on January 19, 2010. He was re-elected in November of 2013 and served two full terms as Governor. He left office in January of 2018
During his time in office, Governor Christie emphasized the issues of fiscal responsibility, pension and health benefit reform, education reform and the opioid crisis gripping his state and the nation. He also devised the state’s landmark response to Superstorm Sandy, leading the rebuilding of the New Jersey’s housing, infrastructure and public schools and setting a bi-partisan example for storm recovery.
On March 29, 2017, President Donald J. Trump appointed Governor Christie as Chairman of the President’s Commission on Combating Drug Addiction and the Opioid Crisis. Governor Christie led the Commission on a seven-month investigation of this issue, holding hearings around the country. Prior to his service as Governor, he served as the United States Attorney for the District of New Jersey from January 2002 to December 2008.
Governor Christie authored “Let Me Finish,” a political and personal autobiography, which was published by Hachette Books in January 2019. The book premiered at number five on The New York Times best seller list and stayed on the list for an additional three weeks. He is now a Senior Legal and Political Commentator for ABC News and the Managing Member of the Christie Law Firm and Christie 55 Solutions, LLC in Morristown, NJ.
Governor Christie holds a Bachelor of Arts in political science from the University of Delaware and earned his J.D. from Seton Hall University School of Law. He is also a recipient of Honorary Doctoral degrees from Rutgers University, University of Delaware, Seton Hall University, Monmouth University, and Centenary College.
Governor Christie married his wife Mary Pat in 1986. They have four children: Andrew, Sarah, Patrick and Bridget. They currently reside in Mendham and Bay Head, New Jersey.
Mark I. Froimson, MD
Principal at Riverside Health Advisors
Mark I. Froimson, MD has served as a director since June 2017. He is currently a Principal at Riverside Health Advisors, a consulting company that provides strategic advice and services to health care executive
Mark I. Froimson, MD has served as a director since June 2017. He is currently a Principal at Riverside Health Advisors, a consulting company that provides strategic advice and services to health care executive leaders. Mr. Froimson is the past President of the American Association of Hip and Knee Surgeons (AAHKS). Prior to that, he was the Executive Vice President and Chief Clinical Officer of Trinity Health, a major national non-profit Catholic healthcare system comprising 93 hospitals in 22 states. Before his executive leadership position at Trinity Health, Dr. Froimson was president and chief executive officer of Euclid Hospital, a Cleveland Clinic Hospital. Dr. Froimson served as a staff surgeon in the Department of Orthopedic Surgery at the Cleveland Clinic for over 16 years, during which time he held a variety of leadership positions including president of the professional staff, vice chair of the Orthopedic and Rheumatologic Institute, and member of the Board of Governors and Board of Trustees.
Dr. Froimson received a Bachelor of Science in philosophy from Princeton University, an M.D. from Tulane University School of Medicine and an MBA from the Weatherhead School of Business at Case Western Reserve University.
Yvonne Greenstreet, MBChB, MBA,
Alnylam Pharmaceuticals, Inc
Yvonne Greenstreet has served as a director since March 2014. She has served as Executive Vice President and Chief Operating Officer of Alnylam Pharmaceuticals, a leading RNAi therapeutics company, since September
Yvonne Greenstreet has served as a director since March 2014. She has served as Executive Vice President and Chief Operating Officer of Alnylam Pharmaceuticals, a leading RNAi therapeutics company, since September 2016.
Prior to joining Alnylam, Dr. Greenstreet was Senior Vice President and Head of Medicines Development at Pfizer, from December 2010 to November 2013.
Dr. Greenstreet was also at GlaxoSmithKline (GSK) for 18 years, most recently as Senior Vice President and Chief of Strategy for Research and Development. Dr. Greenstreet previously served in various positions of increasing responsibility at GSK, including Senior Vice President for Medicine Development, in which she led the creation of a new global unit which had responsibility for GSK's musculoskeletal, endocrine, gastrointestinal, ophthalmology and urological disease areas. Prior to this role, she was Chief Medical Officer for GSK Europe, with responsibility for development and medical affairs of GSK’s entire pipeline and product portfolio in the region.
Dr. Greenstreet is currently serves on the advisory board of the Bill and Melinda Gates Foundation, and also currently serves on the board of directors of The American Funds. She served on the board of directors of Moelis & Company (NYSE: MC) from February 2015 until December 2018.
Dr. Greenstreet trained as a physician and earned her medical degree from Leeds University in the UK and her MBA from INSEAD, France.
Mark Kronenfeld, MD
Maimonides Medical Center
Mark Kronenfeld has served as a director since June 2013. He has been the Vice Chairman of Anesthesiology at Maimonides Medical Center, a large tertiary care academic medical center in New York City, since March 2009
Mark Kronenfeld has served as a director since June 2013. He has been the Vice Chairman of Anesthesiology at Maimonides Medical Center, a large tertiary care academic medical center in New York City, since March 2009, and has served as Medical Director of Perioperative Services for Maimonides Medical Center since January 2011. Dr. Kronenfeld is a managing partner of Anesthesia Associates of Boro Park, LP, a private medical practice, and a managing partner of Strategic Medical Management Partners. In 2001, Dr. Kronenfeld founded Ridgemark Capital Management ("Ridgemark"), a healthcare-focused hedge fund that invested in public and private healthcare and biomedical companies. He served as the Managing Partner and Portfolio Manager of Ridgemark from April 2001 to December 2008. Dr. Kronenfeld has founded and/or managed various consulting and investment companies focused on healthcare and medical technologies and has served on and chaired multiple leadership committees for various hospitals and medical centers. Previously, Dr. Kronenfeld taught and practiced adult and pediatric cardiac anesthesia at NYU and was Chief of Cardiac Anesthesiology at Hackensack University Medical Center and President of GMS Anesthesia Associates, a private medical practice.
Dr. Kronenfeld received his bachelor of arts in Biology from SUNY Buffalo, his MD degree and completed his residency in Anesthesiology at the University of California, San Diego School of Medicine, and completed a fellowship in Cardiothoracic Anesthesiology at New York University Medical Center. While an Assistant Professor and Attending Cardiac Anesthesiologist at NYU, Dr. Kronenfeld received and completed a Kellogg-sponsored Fellowship in Health Care Management for Future Leaders in Health Care at NYU's Graduate School of Management.
John P. Longenecker, PhD
John P. Longenecker, PhD, has served as a director since July 2007. From October 2010 to May 2014, he served as president and Chief Executive Officer of HemaQuest Pharmaceuticals, a biopharmaceutical company
John P. Longenecker, PhD, has served as a director since July 2007. From October 2010 to May 2014, he served as president and Chief Executive Officer of HemaQuest Pharmaceuticals, a biopharmaceutical company developing treatment for hemoglobinopathies, including sickle cell disease and beta thalassemia. Dr. Longenecker has 30 years’ experience in the biotech/pharmaceutical industry, including the startup and growth of multiple biotechnology companies. He has led efforts in all aspects of company development from startup venture capital funding, initial and secondary public offerings, corporate partnering, management of collaborations and mergers and acquisitions.
From December 2009 to March 2010, Dr. Longenecker served as the President and Chief Executive Officer of VitreoRetinal Technologies Inc., an ophthalmic biopharmaceutical company. Dr. Longenecker was President, Chief Executive Officer and a Director of Favrille, Inc., a public biotechnology company developing personalized cancer vaccines for lymphoma, from February 2002 to January 2009. In 1992, he joined DepoTech (the precursor to Pacira) as Senior Vice President of Research, Development and Operations, and then served as President and Chief Operating Officer from February 1998 to March 1999. Under his leadership, DepoTech took its lead product, DepoCyt, from early pre-clinical research and development through to commercial launch.
Following SkyePharma PLC’s acquisition of DepoTech in 1999, Dr. Longenecker served as President for the U.S. Operations of SkyePharma Inc. and as a Member of the Executive Committee for SkyePharma PLC. From 1982 to 1992, he was at Scios (Cal Bio), a biotechnology company in the San Francisco Bay Area, where he served as Vice President and Director of Development. He was also a Director of a number of Cal Bio subsidiaries during this period, including Meta Bio and Karo Bio.
Dr. Longenecker obtained a bachelor of science from Purdue University in Lafayette, Indiana and a PhD in Biochemistry from The Australian National University in Canberra, Australia. He was a post-doctoral fellow at Stanford University from 1980 to 1982.
Gary W. Pace, PhD
Dr. Pace has served as a director since June 2008. Dr. Pace has been a director of Simavita Ltd (ASX: SVA) since 2016, Antisense Therapeutics (ASX: ANP) since 2015 and Trovagene, Inc. (Nasdaq: TROV) since 2020 as
Dr. Pace has served as a director since June 2008. Dr. Pace has been a director of Simavita Ltd (ASX: SVA) since 2016, Antisense Therapeutics (ASX: ANP) since 2015 and Trovagene, Inc. (Nasdaq: TROV) since 2020 as well as a director of several private companies. He previously served on the board of Invitrocue (ASX: IVQ) from 2018 to 2019, ResMed Inc. (NYSE: RMD) from 1994 to 2018, Transition Therapeutics Inc. (CDNX:TTH) from 2002 to 2016 and QRxPharma Ltd. (ASX: QRX) from 2001 to 2013.
Dr. Pace is a seasoned biopharmaceutical executive with over 40 years of experience in the industry. He has co-founded several early stage life science companies, where he built products from the laboratory to commercialization.
Dr. Pace has contributed to the development of the biotechnology industry through honorary university appointments and industry and government committees. In 2003, he was awarded a Centenary Medal by the Australian Government “for service to Australian society in research and development,” and in 2011 was named Director of the Year (corporate governance) by the San Diego Directors Forum. Currently, Dr. Pace is a Director of Simavita Ltd (ASX: SVA), Antisense Therapeutics (ASX: ANP), Invitrocue (ASX: IVQ), and several private companies. He is also on the Board of Trovagene Oncology (Nasdaq: TROV). Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar.
Andreas Wicki, PhD
HBM Healthcare Investments AG
Andreas Wicki has served as a director since our inception in December 2006. Dr. Wicki is a life sciences entrepreneur and investor with over 20 years of experience in the pharmaceutical and biotechnology industries
Andreas Wicki has served as a director since our inception in December 2006. Dr. Wicki is a life sciences entrepreneur and investor with over 20 years of experience in the pharmaceutical and biotechnology industries. He has been Chief Executive Officer of HBM Healthcare Investments (Cayman) Ltd. (formerly HBM BioVentures AG) since 2001. Prior to this role, from 1990-1998, he was co-owner and Chief Executive Officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences CRO companies which he then sold to MDS Inc., a major life sciences services and clinical research organization. After the acquisition, from 1998-2001, he was Senior Vice President of the European Analytical Operations at MDS Inc., which allowed him to become more active in private equity investing. He was with HBM Healthcare Investments AG from its founding and was active in the sourcing, financing and development of more than 100 companies, many of which have reached valuations exceeding $1 billion.
From 2007 to 2011, he served as a member of the board of directors of PharmaSwiss SA. Previously, Dr. Wicki held board positions on several privately held companies and companies listed on international exchanges. Dr. Wicki holds an MSc and PhD in chemistry and biochemistry from the University of Bern, Switzerland. He currently serves on the Board of Directors of Buchler GmbH, Harmony Biosciences, Inc., HBM Healthcare Investments (Cayman) Ltd., Viela Bio, Inc. (NASDAQ: VIE), Vitaeris Inc., and HBM BioCapital Ltd.